New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 12, 2009, Pages 3636-3643

  Le Van, Kiet ^a   Cauvin, Christine ^a   De Walque, Stéphane ^b   Georges, Benoît ^a   Boland, Sandro ^a   Martinelli, Valérie ^b   Demonté, Dominique ^b   Durant, François ^a   Hevesi, László ^a   Van Lint, Carine ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3',5' DIMETHYLCYCLOHEXYLOXY) 3,5 DIETHYL 6 METHYL 1H PYRIDIN 2 ONE; 4 (3',5' DIMETHYLCYCLOHEXYLOXY) 5 ETHYL 3 ISOPROPYL 6 METHYL 1H PYRIDIN 2 ONE; EFAVIRENZ; NEVIRAPINE; PYRIDONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ANTI-HIV AGENTS; BINDING SITES; CELL LINE; CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HIV; HIV REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67549128954     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801438e     Document Type: Article

References (30)

1. De Clercq, E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 2001, 8 (13), 1543-1572. (Pubitemid 33076802)
2. Smerdon, S. J.; Jäger, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for non nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915. (Pubitemid 24139542)
3. Arnold, E.; Das, K.; Ding, J.; Yadav, P. N. S.; Hsiou, Y.; Boyer, P. L.; Hughes, S. H. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des. Discovery 1996, 13, 29-47. (Pubitemid 26172880)
4. (a) De Clercq, E. Non nucleoside reverse transcriptase inhibitors (NNRTI): past, present and future. Chem. Biodiversity 2004, 1, 44-64.
5. (b) Minuto, J. J.; Haubrich, R. Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Future HIV Ther. 2008, 2 (6), 525-537.
6. (a) Hammer, S. M.; Saag, M. S.; Schechter, M.; Montaner, J. S.; Schooley, R. T.; Jacobsen, D. M.; Thompson, M. A.; Carpenter, C. C.; Fischl, M. A.; Gazzard, B. G.; Gatell, J. M.; Hirsch, M. S.; Katzenstein, D. A.; Richman, D. D.; Vella, S.; Yeni, P. G.; Volberding, P. A. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA, J. Am. Med. Assoc. 2006, 296 (7), 827-843. (Pubitemid 44223106)
7. (b) De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33 (4), 307-320.
8. Hirsch, M. S.; Brun-Vezinet, F.; Clotet, B.; Conway, B.; Kuritzkes, D. R.; D'Aquila, R. T.; Demeter, L. M.; Hammer, S. M.; Johnson, V. A.; Loveday, C.; Mellors, J. W.; Jacobson, D. M.; Richman, D. D. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society - USA Panel. Clin. Infect. Dis. 2003, 37, 113-128.
9. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Gaul, S. L.; Saari, W. S.; Wai, J. S. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88 (15), 6863-6867. (Pubitemid 21915050)
10. Dolle, V.; Fan, E.; Nguyen, C. H.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Jamieson, G.; Tarrago-Litvak, L.; Bisagni, E. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J. Med. Chem. 1995, 38 (23), 4679-4686.
11. Dolle, V.; Nguyen, C. H.; Legraverend, M.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Ventura, M.; Tarrago-Litvak, L.; Bisagni, E. Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. J. Med. Chem. 2000, 43 (21), 3949-3962. (Pubitemid 30803345)
12. Benjahad, A.; Croisy, M.; Monneret, C.; Bisagni, E.; Mabire, D.; Coupa, S.; Poncelet, A.; Csoka, I.; Guillemont, J.; Meyer, C.; Andries, K.; Pauwels, R.; De Bethune, M.-P.; Himmel, D. M.; Das, K.; Arnold, E.; Nguyen, C. H.; Grierson, D. S. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3- amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. J. Med. Chem. 2005, 48 (6), 1948-1964. (Pubitemid 40396325)
13. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside Inhibitors. J. Med. Chem. 1996, 39 (8), 1589-1600. (Pubitemid 26124233)
14. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267 (3), 727-748. (Pubitemid 27170693)
15. Discover 3; Accelrys Inc.: San Diego, CA.
16. Insight II; Accelrys Inc.: San Diego, CA.
17. Himmel, D. M.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J. Med. Chem. 2005, 48 (24), 7582-7591. (Pubitemid 41698799)
18. Bacheler, L.; Jeffrey, S.; Hanna, G.; D'Aquila, R.; Wallace, L.; Logue, K.; Cordova, B.; Hertogs, K.; Larder, B.; Buckery, R.; Baker, D.; Gallagher, K.; Scarnati, H.; Tritch, R.; Rizzo, C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 2001, 75 (11), 4999-5008. (Pubitemid 32448520)
19. (a) Das, K.; Lewi, P. J.; Hugues, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88, 209-231. (Pubitemid 39579659)
20. (b) Ren, J.; Stammers, D. K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 2008, 134 (1-2), 157-170.
21. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Boyer, P. L.; Lewi, P.; Janssen, P. A.; Kleim, J.-P.; Rösner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 2001, 309, 437-445. (Pubitemid 32564904)
22. Tanaka, H.; Baba, M.; Hayakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; Balzarini, J.; De Clercq, E. A new class of HIV-1 specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogs of 1-[(2-hydroxyethoxy)methyl]- 6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34 (1), 349-357.
23. Fujiwara, T.; Sato, A.; el-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1998, 42 (6), 1340-1345.
24. Balzarini, J.; Pelemans, H.; Esnouf, R.; De Clercq, E. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res. Hum. Retroviruses 1998, 14 (3), 255-260. (Pubitemid 28084020)
25. Clavel, F.; Charneau, P. Fusion from without directed by human immunodeficiency virus particles. J. Virol. 1994, 68 (2), 179-185. (Pubitemid 24022223)
26. Wei, X.; Decker, J. M.; Liu, H.; Zhang, Z.; Arani, R. B.; Kilby, J. M.; Saag, M. S.; Wu, X.; Shaw, G. M.; Kappes, J. C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46 (6), 1896-1905. (Pubitemid 34535213)
27. Spek, A. L. PLATON; University of Utrecht: Utrecht, The Netherlands, 2001.
28. CurveExpert1.3: A Comprehensive Curve Fitting Package for Windows.
29. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods. 1988, 20 (4), 309-321. (Pubitemid 18231639)
30. Stevens, M.; Pannecouque, C.; De Clercq, E.; Balzarini, J. Inhibition of HIV by a new class of pyridine oxide derivatives. Antimicrob. Agents Chemother. 2003, 47 (9), 2951-2957.